Cornick N A, Cuchural G J, Snydman D R, Jacobus N V, Iannini P, Hill G, Cleary T, O'Keefe J P, Pierson C, Finegold S M
Department of Medicine, New England Medical Center, Boston, MA 02111.
J Antimicrob Chemother. 1990 Jun;25(6):1011-9. doi: 10.1093/jac/25.6.1011.
A nationwide survey to monitor the susceptibility of the Bacteroides fragilis group, which began in 1981, was continued during 1987. In addition to the eleven drugs evaluated in 1986, sulbactam, a potent beta-lactamase inhibitor, was tested alone and in combination with ampicillin and cefoperazone. Imipenem, ampicillin/sulbactam, cefoperazone/sulbactam, and ticarcillin/clavulanic acid were the most active newer drugs tested, with less than 1% resistance rates. Chloramphenicol, metronidazole and clindamycin also had excellent activity with resistance rates of 0%, 0%, and 3% respectively. Resistance rates to cefoxitin remained stable at 8%. Ceftizoxime and cefotetan had resistance rates of 26% and 29%, respectively. Rates of resistance varied among different institutions and between the various species.
一项始于1981年的监测脆弱拟杆菌群药敏性的全国性调查在1987年继续进行。除了1986年评估的11种药物外，还单独测试了强效β-内酰胺酶抑制剂舒巴坦以及它与氨苄西林和头孢哌酮的组合。亚胺培南、氨苄西林/舒巴坦、头孢哌酮/舒巴坦和替卡西林/克拉维酸是测试的活性最强的新型药物，耐药率低于1%。氯霉素、甲硝唑和克林霉素也具有出色的活性，耐药率分别为0%、0%和3%。对头孢西丁的耐药率稳定在8%。头孢唑肟和头孢替坦的耐药率分别为26%和29%。不同机构之间以及不同菌种之间的耐药率有所不同。
